Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo. The US regulator says Retevmo ...

Eli Lilly is once again expanding its scope in the radiopharmaceuticals space by entering into a multi-target discovery collaboration agreement with private biotech Aktis Oncology. Lilly will give ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.

Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Where will Eli Lilly be in five years? Despite Lilly's huge success in treating diabetes and obesity, it's not the leader in those markets. That honor belongs to Novo Nordisk ( NVO 1.36%), which sells ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; ...